HealthEgyptian firm develops potential Bundibugyo Ebola vaccine

Egyptian pharmaceutical company Minapharm will receive up to $16.5 million from CEPI to advance a potential Bundibugyo Ebola vaccine toward laboratory development and Phase 1 trials. Designed by its Berlin subsidiary ProBioGen, the candidate is among five receiving CEPI support. No vaccine or specific treatment for this strain is currently approved.

Ebolavaccine developmentDRCpublic health

CCGTN★★★★☆2026-08-27 14:15Original